
Zhitong Finance App News, Fudan, Zhangjiang (01349) issued an announcement. The company recently received the “Notice of Acceptance” approved and issued by the China Drug Administration (China Drug Administration). The drug marketing application for aminovaleric acid hydrochloride granules (this drug) developed by the company to assist surgical resection of non-muscle-invasive bladder cancer (this study) was accepted.
Bladder cancer is a malignant tumor with a high recurrence rate. Depending on whether the tumor invades the musculature of the bladder, it can be divided into non-muscle-invasive bladder cancer (NMIBC) and muscle-invasive bladder cancer (MIBC). According to public information, NMIBC accounts for about 75 percent of bladder cancer cases. Transurethral cystectomy (TURBT) is currently the surgical treatment of choice for NMIBC. The goal is complete removal of the tumor. In clinical treatment, tumor remnants after TURBT surgery are an important cause of NMIBC recurrence. Therefore, the company plans to develop this intraoperative fluorescence guidance technology to increase the detection rate of NMIBC during TURBT surgery to help physicians remove tumor tissue more completely, thereby reducing the recurrence rate of patients.
The company obtained an approval notice for the clinical trial of this drug in February 2024, and commenced phase III confirmatory clinical research in March 2025. This study aims to evaluate the efficacy and safety of oral administration of aminolevulic acid hydrochloride granules for fluorescence-guided tumor resection in patients with bladder cancer. Clinical research on the drug has now been completed, and its application for marketing registration was recently accepted.